论文部分内容阅读
应用ＢＣＯＰＰ／ＣＨＯＰ－Ｂ交替联合化疗方案，治疗６０例中度及高度恶性非何杰金淋巴瘤（ＮＨＬ），完全缓解率（ＣＲ）为６０％，３年生存率为５６．８％。中度恶性组、体力状况０及１级、临床分期Ⅰ、Ⅱ、Ⅲ期和Ａ组患者３年生存率分别为８０．６％、８７．１％、６３．１％和７４．８％，高度恶性组、体力分级≥２级、Ⅳ期、Ｂ症状和血清乳酸脱氢酶（ＬＤＨ）≥３．３４μｍｏｌ·Ｓ／Ｌ患者预后不良，３年生存率分别为２７．５％、７．０％、３４．２％、１２．８％和２２．５％。上述结果表明本化疗方案更适用于治疗较早期（Ⅰ、Ⅱ、Ⅲ期）的中度恶性ＮＨＬ患者。
Sixty patients with moderate and high grade non-Hodgkin’s lymphoma (NHL) were treated with BCOPP / CHOP-B alternating chemotherapy. The complete response rate (CR) was 60% and the 3-year survival rate was 56.8%. Moderately malignant group, physical status 0 and 1, clinical stage Ⅰ, Ⅱ, Ⅲ and A group of patients with 3-year survival rates were 80.6%, 87.1%, 63.1% and 74.8%, respectively, In the highly malignant group, the physical grade was grade 2 or higher, and the prognosis of patients with stage Ⅳ, B symptoms and serum lactate dehydrogenase (LDH) ≥3.34μmol · S / L were poor. The 3-year survival rates were 27.5%, 7.0 %, 34.2%, 12.8% and 22.5%. The above results show that the chemotherapy regimen is more suitable for the treatment of patients with moderately malignant NHL in the early stages (stage I, II, and III).